cerrar

Global

Global/ BIO2022: Limitless Possibilities Despite Challenges in Capital Markets

David H. Crean, Managing General Partner for Equitos Venture Partners and Cardiff Advisory, highlights news from the recent BIO Convention held face-to-face in San Diego, CA for the first time since the start of the COVID-19 pandemic. After more than…

Global/ New Perspectives on Access to Medicines

The COVID-19 pandemic brought the issue of access to medicines to the forefront. Not only did supply chain disruptions lead to initiatives designed to make sure essential medicines reach patients,…

Global/ Biotech’s Progress Towards Diversity, Equity & Inclusion

How diverse is the biotech workforce? A recent report shows the industry has made progress in terms of diversity, equity, and inclusion (DEI) but still has a way to go.…

Global/ The Road Ahead for Life Sciences Transactions & Financing in 2022

David H. Crean, Managing General Partner for Equitos Venture Partners and Cardiff Advisory, highlights the latest trends and recommendations for business and corporate development transactions and capital financing of life…

In Conversation

BIO2022: Limitless Possibilities Despite Challenges in Capital Markets

David H. Crean, Managing General Partner for Equitos Venture Partners and Cardiff Advisory, highlights news from the recent BIO Convention held face-to-face in San Diego, CA for the first time since the start of the COVID-19 pandemic. After more than two years, the 2022 BIO International Convention (BIO2022) was back in-person in San Diego, California. The conference highlighted the industry’s…

BIO2022: Limitless Possibilities Despite Challenges in…

Jennifer Cannon, SVP Global Head Mammalian Biologics –…

Global / Should Environmental Standards be a Part of GMP Inspections?

Representatives from the US FDA, EMA, WHO and the pharma industry debated over the possible inclusion of environmental impact in future good manufacturing practice (GMP) inspections of drug production sites…

Global/ BIO2022: Limitless Possibilities Despite Challenges in Capital Markets

David H. Crean, Managing General Partner for Equitos Venture Partners and Cardiff Advisory, highlights news from the recent BIO Convention held face-to-face in San Diego, CA for the first time…

Global / Sanofi's Paul Hudson: Maintaining Innovation Momentum

The pandemic era has demonstrated the value of innovation, from the mRNA vaccine breakthrough to the use of new technology. Speaking at the recent FT US Pharma and Biotech Summit…

Global/ Securing Trust in the Global Supply Chain of COVID-19 Vaccines

Public trust in the COVID-19 supply chain has grown, but there is still a strong need for standards, processes, and capabilities to ensure patients across the globe have access to…

Global/ Teva, The Generics Giant Looking for a Comeback

The Israeli giant began as a wholesale drug business more than a century ago and went on to dominate the global generics market until it lost its leadership position in…

Global / COVID-19 Oral Antivirals Expected to Generate USD 32.5 Billion in 2022

With the rise of more transmissible variants and the reduced efficacy of outpatient monoclonal antibody therapies, the market for oral antivirals is expected to climb to new heights this year.…

Global / Carbon emissions: the pharma industry pinpointed as a major polluter

While the pharma industry provides the vital medicines needed to treat diseases and keep populations healthy, it is also responsible for carbon emissions of an intensity almost 55 percent higher…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here